News

By Karen Roman Inventiva S.A. (Nasdaq: IVA) said Axel-Sven Malkomes joined the company as Chief Financial Officer, while Susan Coles and Pamela Herbster started their roles as Chief Legal Officer and Chief People Officer, respectively. The additions come as Inventiva prepares for potential commercialization from the Phase 3 trial of its MASH therapeutic, expected in […]

The mean of analysts' price targets for SELLAS Life Sciences Group, Inc. (SLS) points to a 66.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Sellas Life Sciences Group Inc. (NASDAQ:SLS) is one of the best healthcare penny stocks to buy according to hedge funds. On March 19, Chief Executive Officer Angelos Stergiou reiterated that 2026 is poised to be a pivotal year for Sellas Life Sciences Group Inc. (NASDAQ:SLS). The remarks align with the significant progress the company is […]

SELLAS Life Sciences Group Inc. (NASDAQ:SLS) is one of the popular penny stocks on Robinhood to buy. On March 17, SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) announced that it will present preclinical data on SLS009 at the American Association for Cancer Research annual meeting on April 21, 2026. SLS009, alternatively known as tambiciclib, is a […]

SELLAS Life Sciences Group, Inc. (SLS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

The consensus price target hints at a 63.6% upside potential for SELLAS Life Sciences Group, Inc. (SLS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Assessing recent moves in SELLAS Life Sciences Group (SLS) SELLAS Life Sciences Group (SLS) has drawn attention after a recent run in its share price, with returns over the past 3 months and year that stand out against its mixed multi year track record. Over the past month the stock shows a gain, alongside a much stronger move in the past 3 months and a very large 1 year total return, while 5 year performance remains negative. That mix often prompts investors to revisit the story behind the...

A late-stage clinical biopharmaceutical company focused on immunotherapy for various cancers, SELLAS Life Sciences Group (NASDAQ:SLS) is at a genuinely unusual inflection point. Its shares have climbed 346% over the past year, yet the stock pulled back 13.4% in the past week to $5.04, with Q4 earnings due March 19. The reason Reddit is buzzing: ... SELLAS Stock Up 346% in a Year as Cancer Vaccine Trial Nears Its Final 8 Deaths

In late 2025, SELLAS Life Sciences Group reported encouraging Phase 2 data for SLS009 in combination with azacitidine and venetoclax in relapsed or refractory acute myeloid leukemia and confirmed that its Phase 3 REGAL trial of Galinpepimut-S would continue unchanged after an Independent Data Monitoring Committee review. Taken together, these developments highlight both near-term clinical momentum around SLS009 and growing validation of Galinpepimut-S as a potential maintenance therapy in...

SELLAS Life Sciences Group (SLS) is back in focus after encouraging clinical updates on its leukemia programs, including Phase 2 data for SLS009 and ongoing progress in the Phase 3 REGAL trial for Galinpepimut S. See our latest analysis for SELLAS Life Sciences Group. The recent clinical updates appear to be reflected in momentum, with a 44.8% 1 month share price return, a 217.8% 3 month share price return and a very large 1 year total shareholder return, although the 5 year total shareholder...